Oncolytics Biotech (ONCY) Posts Wider Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
March 3, 2022 4:01 PM ESTRandomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022
Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker a key finding for de-risking a phase 3 registrational breast cancer study
Interim safety updates from clinical trials in triple-negative breast and gastrointestinal cancers further demonstrate the favorable safety profile of pelareorep-checkpoint inhibitor combinations
Strong financial position with approximately $41.3 million and cash runway through key milestones and into 2023
Management hosting conference call and webcast today at 5:00 p.m.... More
